Amedisys, Inc.

NasdaqGS:AMED Rapport sur les actions

Capitalisation boursière : US$3.2b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Amedisys Gestion

Gestion contrôle des critères 1/4

Le PDG Amedisys' est Richard Ashworth, nommé en Apr2023, a un mandat de 1.33 ans. La rémunération annuelle totale est $ 16.97M, composée du salaire de 4.1% et des bonus 95.9%, y compris les actions et options de la société. détient directement 0.088% des actions de la société, d'une valeur de $ 2.82M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1.8 ans et 4.8 ans.

Informations clés

Richard Ashworth

Directeur général

US$17.0m

Rémunération totale

Pourcentage du salaire du PDG4.1%
Durée du mandat du directeur général1.3yrs
Propriété du PDG0.09%
Durée moyenne d'occupation des postes de direction1.8yrs
Durée moyenne du mandat des membres du conseil d'administration4.8yrs

Mises à jour récentes de la gestion

Recent updates

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Apr 10
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Feb 25
Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Feb 10
Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jan 03
At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Dec 16
A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Nov 12
Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

Sep 19
Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04
An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04
Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20
We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04
At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05
Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20
Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06
Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20
Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19
Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18
These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18
Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23
Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28
Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02
It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24
Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Analyse de la rémunération des PDG

Comment la rémunération de Richard Ashworth a-t-elle évolué par rapport aux bénéfices de Amedisys?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

US$92m

Mar 31 2024n/an/a

-US$21m

Dec 31 2023US$17mUS$692k

-US$10m

Rémunération vs marché: La rémunération totale de Richard ($USD 16.97M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 6.76M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Richard avec les performances de l'entreprise.


PDG

Richard Ashworth (49 yo)

1.3yrs

Titularisation

US$16,974,025

Compensation

Mr. Richard M. Ashworth served as Director at Tivity Health, Inc. since June 1, 2020 until April 2023 and had been its President since June 1, 2020 and served as its Chief Executive Officer since June 1, 2...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Richard Ashworth
President1.3yrsUS$16.97m0.088%
$ 2.8m
Scott Ginn
Executive VP6.8yrsUS$4.45m0.077%
$ 2.5m
Michael North
Chief Information Officer7.8yrsUS$1.55m0.033%
$ 1.0m
Denise Bohnert
Chief Compliance Officer4.9yrsUS$1.28mpas de données
Nick Muscato
Chief Strategy Officerno dataUS$1.37m0.0065%
$ 208.6k
Allyson Guidroz
Chief Accounting Officer & Principal Accounting Officerless than a yearpas de données0.0097%
$ 310.3k
Pete Hartley
CTO & Senior VP of Business Operations Systemsno datapas de donnéespas de données
Jennifer Griffin
Senior VP1.8yrspas de donnéespas de données
Kendra Kimmons
VP of Marketing & Communications & Media Relationsno datapas de donnéespas de données
Caitlin Franklin
Acting Chief People Officerless than a yearpas de donnéespas de données
Francis Mayer
Senior Vice President of Developmentno datapas de donnéespas de données

1.8yrs

Durée moyenne de l'emploi

49yo

Âge moyen

Gestion expérimentée: L'équipe de direction de AMED n'est pas considérée comme expérimentée (ancienneté moyenne 1.8 ans), ce qui suggère une nouvelle équipe.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Richard Ashworth
President1.3yrsUS$16.97m0.088%
$ 2.8m
Paul Kusserow
Chairman9.7yrsUS$4.00m1.33%
$ 42.8m
Bruce Perkins
Independent Director9.3yrsUS$267.62k0.063%
$ 2.0m
Vickie Capps
Independent Director4.8yrsUS$277.62k0.020%
$ 632.2k
Molly Coye
Independent Director4.8yrsUS$267.62k0.017%
$ 534.3k
Julie Klapstein
Lead Independent DIrector8.3yrsUS$282.62k0.039%
$ 1.2m
Jeffrey Rideout
Independent Director8.3yrsUS$267.62k0.018%
$ 585.0k
Teresa Kline
Independent Director4.8yrsUS$272.62k0.020%
$ 632.2k
Ivanetta Samuels
Independent Director3.7yrsUS$252.62k0.013%
$ 414.9k

4.8yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de AMED sont considérés comme expérimentés (ancienneté moyenne 4.8 ans).